Published in Nat Nanotechnol on September 29, 2013
A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods (2015) 1.43
Rare cell isolation and analysis in microfluidics. Lab Chip (2014) 1.42
Microfluidic cell sorting: a review of the advances in the separation of cells from debulking to rare cell isolation. Lab Chip (2015) 1.09
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget (2014) 1.08
Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip (2014) 1.03
Emerging role of nanomaterials in circulating tumor cell isolation and analysis. ACS Nano (2014) 1.00
Point-of-care technologies for molecular diagnostics using a drop of blood. Trends Biotechnol (2014) 0.99
Aptamer-conjugated graphene oxide membranes for highly efficient capture and accurate identification of multiple types of circulating tumor cells. Bioconjug Chem (2015) 0.94
Electrochemical sensors and biosensors based on nanomaterials and nanostructures. Anal Chem (2014) 0.92
Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater (2015) 0.91
Cascaded spiral microfluidic device for deterministic and high purity continuous separation of circulating tumor cells. Biomicrofluidics (2014) 0.88
A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small (2014) 0.88
Molecular profiling of single circulating tumor cells from lung cancer patients. Proc Natl Acad Sci U S A (2016) 0.87
Effects of nanopillar array diameter and spacing on cancer cell capture and cell behaviors. Nanoscale (2014) 0.85
Highly stable aptamers selected from a 2'-fully modified fGmH RNA library for targeting biomaterials. Biomaterials (2015) 0.84
Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells. Biomicrofluidics (2015) 0.82
High-purity isolation and recovery of circulating tumor cells using conducting polymer-deposited microfluidic device. Theranostics (2014) 0.82
Programming thermoresponsiveness of NanoVelcro substrates enables effective purification of circulating tumor cells in lung cancer patients. ACS Nano (2014) 0.82
In vivo capture and label-free detection of early metastatic cells. Nat Commun (2015) 0.81
Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies. J Biomed Mater Res A (2015) 0.80
Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies. Anal Chem (2014) 0.80
Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial. J Nanobiotechnology (2015) 0.80
Extracorporeal photo-immunotherapy for circulating tumor cells. PLoS One (2015) 0.80
Nanotechnology for enrichment and detection of circulating tumor cells. Nanomedicine (Lond) (2015) 0.80
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
Multifunctional biocompatible graphene oxide quantum dots decorated magnetic nanoplatform for efficient capture and two-photon imaging of rare tumor cells. ACS Appl Mater Interfaces (2015) 0.80
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. Front Oncol (2015) 0.79
Fabrication of SnO₂-reduced graphite oxide monolayer-ordered porous film gas sensor with tunable sensitivity through ultra-violet light irradiation. Sci Rep (2015) 0.79
Multivalent conjugation of antibody to dendrimers for the enhanced capture and regulation on colon cancer cells. Sci Rep (2015) 0.79
Chemically Modified Plastic Tube for High Volume Removal and Collection of Circulating Tumor Cells. PLoS One (2015) 0.79
Screening and Molecular Analysis of Single Circulating Tumor Cells Using Micromagnet Array. Sci Rep (2015) 0.79
Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. Theranostics (2016) 0.78
Comparison study of distinguishing cancerous and normal prostate epithelial cells by confocal and polarization diffraction imaging. J Biomed Opt (2016) 0.78
Rational Design of Materials Interface for Efficient Capture of Circulating Tumor Cells. Adv Sci (Weinh) (2015) 0.77
Recent advances in nanotechnology-based detection and separation of circulating tumor cells. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.77
Real-time Detection of Breast Cancer Cells Using Peptide-functionalized Microcantilever Arrays. Sci Rep (2015) 0.77
Ultrasensitive microfluidic analysis of circulating exosomes using a nanostructured graphene oxide/polydopamine coating. Lab Chip (2016) 0.77
The liquid biopsy in lung cancer. Genes Cancer (2016) 0.76
The incorporation of microfluidics into circulating tumor cell isolation for clinical applications. Curr Opin Chem Eng (2016) 0.76
Graphene Oxide Nanosheets Modified with Single-Domain Antibodies for Rapid and Efficient Capture of Cells. Chemistry (2015) 0.76
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs (2015) 0.76
An electrochemical immunosensing method for detecting melanoma cells. Biosens Bioelectron (2015) 0.75
Graphene Oxide Nanosheets Stimulate Ruffling and Shedding of Mammalian Cell Plasma Membranes. Chem (2016) 0.75
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. Eur J Cardiothorac Surg (2014) 0.75
HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res (2016) 0.75
Enrichment and single-cell analysis of circulating tumor cells. Chem Sci (2016) 0.75
New technology: nanotechnology targets cancer cells. Nat Rev Clin Oncol (2013) 0.75
Research Highlights: highlights from the latest articles in nanomedicine. Nanomedicine (Lond) (2014) 0.75
Interactions of calcium with the external surfaces of fullerenes and endofullerenes doped with radioactive sodium iodide. J Mol Model (2016) 0.75
Circulating Tumor Cells: Moving Biological Insights into Detection. Theranostics (2017) 0.75
Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells. Cell Mol Bioeng (2017) 0.75
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A (2008) 10.09
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
The chemistry of graphene oxide. Chem Soc Rev (2009) 6.93
Large-area ultrathin films of reduced graphene oxide as a transparent and flexible electronic material. Nat Nanotechnol (2008) 6.32
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc (2008) 4.11
Nano-Graphene Oxide for Cellular Imaging and Drug Delivery. Nano Res (2008) 3.80
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Functionalized graphene sheets for polymer nanocomposites. Nat Nanotechnol (2008) 3.45
Highly conducting graphene sheets and Langmuir-Blodgett films. Nat Nanotechnol (2008) 3.32
Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol (2012) 2.81
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl (2009) 1.86
Graphene-based single-bacterium resolution biodevice and DNA transistor: interfacing graphene derivatives with nanoscale and microscale biocomponents. Nano Lett (2008) 1.81
An index for characterization of nanomaterials in biological systems. Nat Nanotechnol (2010) 1.69
Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol (2011) 1.50
Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev (2012) 1.47
Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev (2011) 1.39
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer (2010) 1.37
Electrospun TiO2 nanofiber-based cell capture assay for detecting circulating tumor cells from colorectal and gastric cancer patients. Adv Mater (2012) 1.30
Nanowire substrate-based laser scanning cytometry for quantitation of circulating tumor cells. Nano Lett (2012) 1.19
Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res (2012) 1.09
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat (2012) 0.96
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res (2009) 6.43
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Stem cells in normal breast development and breast cancer. Cell Prolif (2003) 4.47
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev (2006) 3.72
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 3.21
Pancreatic cancer stem cells. J Clin Oncol (2008) 3.21
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2012) 2.80
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol (2005) 2.69
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract (2010) 2.59
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2012) 2.53
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 2.50
An international Ki67 reproducibility study. J Natl Cancer Inst (2013) 2.46
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol (2012) 2.44
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34
Is there still a glass ceiling for women in academic surgery? Ann Surg (2011) 2.33
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology (2011) 2.27
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study. J Korean Med Sci (2013) 2.23
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol (2007) 2.20
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol (2010) 2.14
Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia (2005) 2.13
Cancer stem cells: a step toward the cure. J Clin Oncol (2008) 2.08
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol (2012) 2.05
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med (2009) 2.04
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res (2009) 2.04
Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell (2009) 2.04
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res (2007) 2.02
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol (2014) 1.99
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res (2010) 1.96
Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res (2008) 1.95
S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res (2005) 1.95
InterDom: a database of putative interacting protein domains for validating predicted protein interactions and complexes. Nucleic Acids Res (2003) 1.94
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91